- BELLUS to provide BLU-5937 program update,
Key Opinion Leader Dr. Jacky Smith
to present on chronic cough -
LAVAL, QC, Sept. 20, 2017
/CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the
Company), a biopharmaceutical development company advancing novel
therapeutics for conditions with high unmet medical need, will host
a chronic cough Key Opinion Leader (KOL) presentation and BLU-5937
program update today at 2:00 PM
ET.
To listen to the live webcast or to ask questions during the
live event, please register at the following link:
https://event.webcasts.com/starthere.jsp?ei=1159556&tp_key=4a0ae58b66.
An archived version of the webcast and presentation will be
available on the Company's website at www.bellushealth.com
following the event.
The event will feature a presentation by KOL Dr. Jacky Smith, Professor of Respiratory Medicine
at the University of Manchester
and Director of the NIHR South Manchester Respiratory and Allergy
Clinical Research Facility. Dr. Smith will discuss the clinical
presentation of chronic cough, its current unmet medical need and
therapeutic options, as well as novel treatment approaches under
development.
Dr. Denis Garceau, BELLUS
Health's Senior Vice President, Drug Development, will also provide
an update on the BLU-5937 program, including recent study results
that show a significant reduction in cough with no taste
disturbance in two separate preclinical models. In the guinea pig
cough model, BLU-5937 demonstrated comparable efficacy to the
current leading P2X3 antagonist, Merck & Co's Gefapixant (also
named AF-219 or MK-7264). In the rat taste model, BLU-5937 did not
show taste inhibition; however, consistent with clinical trial data
previously presented by Merck & Co, Gefapixant did
significantly impact taste.
Both Dr. Smith and Dr. Garceau will be available to answer
questions at the end of their presentations.
About BLU-5937
BLU-5937, a selective P2X3 antagonist, has the potential to be a
best-in-class therapeutic for chronic cough patients who do not
respond to current therapies. Chronic cough is a cough that lasts
more than eight weeks and is associated with significant adverse
social, psychosocial and physical effects on quality of life. It is
estimated that more than 2.7 million patients suffer from
refractory chronic cough in the United
States alone.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a biopharmaceutical development company
advancing novel therapeutics for conditions with high unmet medical
need. Its pipeline of projects includes BLU-5937 for chronic cough
and several other partnered clinical-stage drug development
programs.
Forward-Looking Statements
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute "forward-looking statements" within the
meaning of Canadian securities legislation and regulations. Such
statements, based as they are on the current expectations of
management, inherently involve numerous important risks,
uncertainties and assumptions, known and unknown, many of which are
beyond BELLUS Health Inc.'s control. Such risks factors include but
are not limited to: the ability to expand and develop its project
pipeline, the ability to obtain financing, the impact of general
economic conditions, general conditions in the pharmaceutical
industry, changes in the regulatory environment in the
jurisdictions in which BELLUS Health Inc. does business, stock
market volatility, fluctuations in costs, changes to the
competitive environment due to consolidation, achievement of
forecasted burn rate, potential payments/outcomes in relation to
indemnity agreements and contingent value rights, achievement of
forecasted pre-clinical and clinical trial milestones and that
actual results may vary once the final and quality-controlled
verification of data and analyses has been completed. In addition,
the length of BELLUS Health Inc.'s drug candidates' development
process, their market size and commercial value, as well as the
sharing of proceeds between BELLUS Health Inc. and its potential
partners from potential future revenues, if any, are dependent upon
a number of factors. Consequently, actual future results and events
may differ materially from the anticipated results and events
expressed in the forward-looking statements. The Company believes
that expectations represented by forward-looking statements are
reasonable, yet there can be no assurance that such expectations
will prove to be correct. The reader should not place undue
reliance, if any, on any forward-looking statements included in
this news release. These forward-looking statements speak only as
of the date made, and BELLUS Health Inc. is under no obligation and
disavows any intention to update publicly or revise such statements
as a result of any new information, future event, circumstances or
otherwise, unless required by applicable legislation or regulation.
Please see BELLUS Health Inc.'s public filings with the Canadian
securities regulatory authorities, including the Annual Information
Form, for further risk factors that might affect BELLUS Health Inc.
and its business.
SOURCE BELLUS Health Inc.